December 2010 – eResearchTechnology, Inc. (ERT) and CROss Alliance announce their Joint Marketing Agreement, to mutually promote the activities of both organizations.
After a successful collaboration of several years in QTc prolongation studies, CROss Alliance and ERT have developed a mutually successful and meaningful working relationship. CROss Alliance has recently selected ERT as a preferred cardiac safety provider for all trials to be performed at the CROss Research Phase I unit in Switzerland and in support of all CROss trials around Europe.
ERT has included CROss research Phase I unit among their recommended Clinical Phase I units in Europe.
A broad range of joint marketing activities will be performed through the year, including joint client visits, preparation of promotion documentation and joint attendance at Congresses.
The next common attended event will be DIA EuroMeeting in Geneva from the 28th to 30th of March. During DIA, you can meet with Business Development Managers and Accounts Executives from both companies, who will be happy to explain the advantages of collaborating with both companies in your next cardiac safety trial.
ERT has included CROss research Phase I unit among their recommended Clinical Phase I units in Europe.
A broad range of joint marketing activities will be performed through the year, including joint client visits, preparation of promotion documentation and joint attendance at Congresses.
The next common attended event will be DIA EuroMeeting in Geneva from the 28th to 30th of March. During DIA, you can meet with Business Development Managers and Accounts Executives from both companies, who will be happy to explain the advantages of collaborating with both companies in your next cardiac safety trial.
Based on the expertise and reliability of CROSS and ERT, this agreement is certain to provide continued high quality services to our clients.
To learn more about ERT and CROss Alliance services visit www.ert.com and www.croalliance.com